Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) issued Final Written Decisions invalidating all claims in 10x Genomics’
Genomics
In a sign of its ambition to expand its foothold in genomics and grow its contribution to global genomics diversity, M42 and Uzbekistan’s Ministry of Health have signed a Memorandum of Understanding (“MoU”) to collaborate and explore opportunities for strategic partnerships on the Uzbek Genome Program. Coinciding with an official visit by the President of Uzbekistan
M42, a global health leader powered by artificial intelligence (AI) and technology, is set to lead conversations and debates on the critical areas for local and international collaboration to support global progress in healthcare at Arab Health 2025. As the Global Health Partner at the event, M42’s Managing Director and Group Chief Executive Officer, Hasan […]
M42’s advancements in laboratory medicine and genomics to take center stage at ADLM Middle East 2024
M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and genomics-driven medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. The largest healthcare company in the Middle East will showcase the unparalleled spectrum of diagnostic capabilities at the ADLM Middle East Conference
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, M42, the global tech-enabled health leader, and Khalifa University will showcase Abu Dhabi’s advancements in genomics and precision medicine at the American Society of Human Genetics (ASHG) 2024 Annual Meeting from 5-9 November 2024, in Denver, Colorado, US. […]